1. Home
  2. PVL vs ACXP Comparison

PVL vs ACXP Comparison

Compare PVL & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

HOLD

Current Price

$1.83

Market Cap

60.7M

Sector

Energy

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.40

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PVL
ACXP
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.7M
6.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PVL
ACXP
Price
$1.83
$1.40
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
62.7K
176.5K
Earning Date
03-20-2026
05-12-2026
Dividend Yield
7.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$1.31
52 Week High
$2.04
$8.34

Technical Indicators

Market Signals
Indicator
PVL
ACXP
Relative Strength Index (RSI) 61.37 44.95
Support Level $1.73 $1.34
Resistance Level $1.92 $1.75
Average True Range (ATR) 0.04 0.05
MACD 0.00 -0.00
Stochastic Oscillator 66.67 12.93

Price Performance

Historical Comparison
PVL
ACXP

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: